Site for A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis

Go Back to All Clinical Trials

Site for A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis

Brief description of study

Site for The purpose of this study is to measure clinical efficacy (based on TIS) of oral brepocitinib compared with placebo in participants with dermatomyositis

Clinical Study Identifier: s22-00734

ClinicalTrials.gov Identifier: NCT05437263

Principal Investigator: Alisa N Femia.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies